Latest Breaking News On - ஹால் துப்பாக்கி - Page 1 : comparemela.com

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform VANCOUVER, British Columbia, Dec. 18, 2020 Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the potential application of Qu’s lung-directed SSI, QBKPN, to prevent and treat infection with SARS-CoV-2, the virus causing COVID-19. Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qu’s immunotherapy platform engages and trains the innate arm of the

United kingdomBritish columbiaHal gunnSimon sutcliffeHuman health therapeutics research centreMcmaster universityDartmouth collegeBc cancer agencyQu biologics incSite specific immunomodulatorsNational research councilCanada industrial research assistance programShirin kalyanVice presidentScientific innovationChief medical officer